Clinical Multicenter Randomized Controlled Study of Simultaneous Cognitive Training With Transcranial Magnetic Stimulation in the Treatment of VaD-MCI Patients

Launched by XUANWU HOSPITAL, BEIJING · Jun 17, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment approach for patients with vascular cognitive impairment with dementia (VaD-MCI), a condition that affects memory and thinking skills. The study will look at how combining cognitive training, which helps improve mental functions, with a technique called transcranial magnetic stimulation (TMS) can help these patients. TMS is a non-invasive method that uses magnetic fields to stimulate nerve cells in the brain. The goal is to determine if this combined approach is effective and safe for improving cognitive function in people with VaD-MCI.

To be eligible for this trial, participants must be between the ages of 50 and 85 and have a specific score on a mental evaluation test that measures cognitive function. They should also have certain brain imaging results that show specific types of brain changes related to their condition. However, individuals with serious cognitive impairment, neurological diseases, or significant physical disabilities that prevent them from participating in the assessments will not be included. While the trial is not currently recruiting participants, those who take part can expect to undergo cognitive training sessions alongside TMS treatment and will contribute to important research aimed at developing better treatment options for cognitive impairment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female VaD-MCI patients between the ages of 50-85; The psychological evaluation was in accordance with MMSE score of 18-26 (including 18 and 26) and CDR score of 0.5.
• • The inclusion criteria based on MRI examination include: ① Multiple supratentorial subcortical lacunae (3-20 mm) with or without white matter degeneration, or moderate and severe white matter degeneration (Fazekas score ≥2) with or without lacunae; ② White matter lesions such as cortical/watershed infarction, cerebral hemorrhage, hydrocephalus or other causes (such as multiple sclerosis) were excluded; ③ There was no medial atrophy of hippocampus or temporal lobe (MTA 0); Can cooperate to complete clinical research.
• Exclusion Criteria:
• • Suffering from any cause of disturbance of consciousness. Severe aphasia or physical disability can not complete the neuropsychological examination Those who have a history of alcoholism, or drug addiction, or neurological diseases such as brain trauma, epilepsy, encephalitis, normal intracranial pressure hydrocephalus, etc. that can cause cognitive impairment.
• • Suffering from systemic diseases that may lead to cognitive impairment (such as liver and kidney insufficiency, endocrine diseases, vitamin deficiency).
• • Have a history of using antipsychotics for more than five years before diagnosis.
• • There are contraindications for head MRI examination.